Acorn Management Partners, LLC

Our client Zevra $ZVRA Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Revie...